#Netherlands #Amsterdam #CGM #SIBIONICS #GS3

Introduction

The 2025 Advanced Technologies & Treatments for Diabetes (ATTD) conference held in Amsterdam showcased significant innovations in diabetes care, and one standout participant was SIBIONICS. This year, they introduced the GS3, which has now earned the title of the world's thinnest continuous glucose monitor (CGM), measuring only 2.9mm in thickness.

A Game-Changer in Glucose Monitoring

The GS3's ultra-slim design not only enhances portability but also provides unmatched convenience for users. Weighing in at a mere 1.5 grams, this device is so light it often goes unnoticed when worn. This feature is especially beneficial for those who need to monitor their glucose levels continuously without the added bulk of traditional monitors.

Seamless Connectivity Options

The GS3 is equipped with three different connection methods, ensuring compatibility with a variety of smartphones. An NFC-enabled 3-second pairing technology allows users to connect with ease—just a simple touch is all it takes. This emphasis on user experience allows individuals to focus on their daily activities without the distraction of cumbersome technology.

Empowering Diabetes Management with AI

SIBIONICS has integrated advanced artificial intelligence capabilities into the GS3 to help users make more informed decisions regarding their glucose monitoring. The device facilitates easier self-management of glucose levels, making it especially suitable for pediatric and geriatric patients who may require tailored healthcare solutions.

Additionally, the ongoing algorithm enhancements promise more stable monitoring and greater accuracy—key components for effective diabetes management.

SIBIONICS Symposium: Insights into CGM Technology

During the ATTD 2025, SIBIONICS also organized a symposium aimed at educating healthcare professionals on the clinical applications of CGM technology. At the event, experts presented their findings on the Ambulatory Glucose Profile (AGP) patterns, shedding light on how different patient groups react to various monitoring methods.

One standout presentation discussed the Clinical Knowledge Management (CKM) tool that was introduced at the symposium. Initial studies indicated its promising role in managing Type 1 diabetes, marking a significant step forward in understanding how best to utilize CGM technologies for patient care.

SIBIONICS: Transforming Healthcare Since 2015

Founded in 2015, SIBIONICS has made tremendous strides in the field of medical devices with a dedication to innovation and excellence. With offices in Shenzhen, China, and Irvine, California, the company employs over 500 staff members, of whom more than 25% are R&D scientists from top global universities. The mission of SIBIONICS is clear: to enhance patient lives through insightful healthcare technology.

Combining state-of-the-art continuous biosensors with intuitive software solutions, the company aims to deliver deeper insights into health, thus improving overall treatment experiences.

Conclusion

With the GS3, SIBIONICS is setting a new benchmark in glucose monitoring technology. By offering a lighter, more accurate, and user-friendly solution for individuals with diabetes, SIBIONICS is poised to revolutionize the way glucose data is interpreted and managed. As ongoing improvements continue to enhance its functionalities, the GS3 represents just the beginning of what’s possible in diabetes care—marking a noteworthy progression for both the company and patients worldwide.